2023-06-19 02:08:39
Money Today Reporter Kim Do-yoon | 2023.06.19 11:08
Intron Bio announced on the 19th that it has confirmed the broad-spectrum antibacterial efficacy of ‘EFL2200’, a bio new drug targeting VRE (Vancomycin-resistant Enterococci).
VRE is one of the resistant bacteria that poses a serious threat to human health, warned by the US Centers for Disease Control and Prevention (CDC). When VRE colonizes the intestine, it can lead to blood infection in the elderly as a side effect of immunosuppression or other drug use in the elderly. In particular, caution is needed as it can worsen sepsis, which is the biggest cause of death in the elderly. Sepsis is a terrifying disease with a rapid increase in mortality if not diagnosed within 36 hours of onset and treated appropriately.
Intron Bio’s EFL2200 is a drug against VRE infection. It can be used as a treatment for blood stream infections such as bacteremia and endocarditis. Intronbio is first developing a treatment agent for VRE colonization in the intestines where unmet needs exist for which no suitable treatment method has been developed.
IntronBio explained that in the recent efficacy evaluation of EFL2200, it showed a broad antibacterial spectrum, including antibacterial activity against Enterococcus faecalis.
Enterococcus faecium and Enterococcus faecalis are the major strains that cause VRE infections. In the past, the proportion of Enterococcus faecium tended to increase, but recently, Enterococcus faecalis has also increased again. Both strains are VRE strains that should be treated as important in health care.
Kang Sang-hyun, director of Intron Bio Research Institute, said, “Recently, VRE colonization has emerged as a new social problem due to the aging population, and it is a particularly serious problem for the elderly, such as nursing hospital patients.” It’s a serious situation, but there are currently no effective drugs to treat VRE intestinal colonization.” “Considering the increasing trend of the elderly population, EFL2200 will be a drug that improves the quality of life,” he said. “We expect it to be a drug with good marketability.”
Yoon Kyung-won, CEO of Intron Bio, said, “EFL2200 is a drug with high unmet medical demand, so expectations are high.”
[저작권자 @머니투데이, 무단전재 및 재배포 금지]
1687142535
#Intronbio #VRE #drug #EFL2200 #confirms #broadspectrum #antibacterial #efficacy